Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.69 ^USD	-1.43%		+1.89%	-52.74%

Apr. 25	Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	CI
Jan. 12	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023

January 12, 2024 at 07:43 am EST

Virax Biolabs Group Limited reported earnings results for the half year ended September 30, 2023. For the half year, the company reported sales was USD 0.0765 million compared to USD 0.00576 million a year ago. Net loss was USD 2.91 million compared to USD 1.44 million a year ago.

Basic loss per share from continuing operations was USD 1.64. Diluted loss per share from continuing operations was USD 1.64.

Latest news about Virax Biolabs Group Limited

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	Apr. 25	CI
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Jan. 12	CI
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	Dec. 21	CI
Top Premarket Gainers	Dec. 12	MT
Virax Biolabs Group Limited announced that it has received $2.15 million in funding	23-10-16	CI
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding	23-10-11	CI
Virax Biolabs Group Names Nigel McCracken Operating Chief.	23-09-01	MT
Virax Biolabs Group Limited Announces Management Changes	23-09-01	CI
Certain Ordinary Shares of Virax Biolabs Group Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.	23-07-20	CI
Virax Biolabs Group Limited Signs Contracts to Launch Two New Research and Laboratory Facilities in the United Kingdom	23-07-18	CI
Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-14	CI
Virax Biolabs Group Limited Auditor Raises 'Going Concern' Doubt	23-06-13	CI
Virax Biolabs Group Limited Announces Establishment of Regional Headquarters at Dubai Science Park	23-05-04	CI
Virax Biolabs Group Limited Enters into an Agreement for the Distribution of Marburg Virus PCR Testing Kits	23-04-19	CI
Virax Biolabs Group Limited announced that it has received $4.000001 million in funding	23-03-09	CI
Virax Biolabs Group Limited announced that it expects to receive $4.000001 million in funding	23-03-07	CI
Traders Cautious Ahead of Powell Testimony, Stifling US Equity futures	23-03-07	MT
Virax Biolabs Signs Agreement to Distribute Avian Influenza A Virus Test Kit in the European Union; Shares Surge Pre-Bell	23-03-07	MT
Top Premarket Gainers	23-03-07	MT
Virax Biolabs Group Limited Enters into an Agreement for the Distribution of an Avian Influenza A Virus	23-03-07	CI
Top Premarket Gainers	23-02-27	MT
Cosmos Health Sets First Purchase Order for Virax Biolabs' COVID-19, Influenza Tests	23-02-07	MT
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health	23-02-07	CI
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health	23-02-07	CI
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2022	23-02-02	CI

Chart Virax Biolabs Group Limited

Duration

Period

More charts

Company Profile

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Sector

Biotechnology & Medical Research

Calendar

2024-04-26 - European Society of Clinical Microbiology and Infectious Diseases Global Congress

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRAX BIOLABS GROUP LIMITED	-52.74%	1.63M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research